Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design.
Butler, C.R., Brodney, M.A., Beck, E.M., Barreiro, G., Nolan, C.E., Pan, F., Vajdos, F., Parris, K., Varghese, A.H., Helal, C.J., Lira, R., Doran, S.D., Riddell, D.R., Buzon, L.M., Dutra, J.K., Martinez-Alsina, L.A., Ogilvie, K., Murray, J.C., Young, J.M., Atchison, K., Robshaw, A., Gonzales, C., Wang, J., Zhang, Y., O'Neill, B.T.(2015) J Med Chem 58: 2678-2702
- PubMed: 25695670 
- DOI: https://doi.org/10.1021/jm501833t
- Primary Citation of Related Structures:  
4WY1, 4WY6, 4X2L - PubMed Abstract: 
The identification of centrally efficacious β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease (AD) has historically been thwarted by an inability to maintain alignment of potency, brain availability, and desired absorption, distribution, metabolism, and excretion (ADME) properties ...